In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia

J. E. Karp, R. C. Donehower, J. P. Enterline, G. B. Dole, M. G. Fox, P. J. Burke

Research output: Contribution to journalArticlepeer-review


A predictable increase in the proliferative rate of malignant cells remaining after initial cytoreduction in vivo forms the rationale for timed sequential therapy (TST) with 1-B-D-arabinofuransylcytosine (ara-C) for adult acute myelogenous leukemia (AML). The relationship between in vivo leukemic cell growth, intracellular ara-C metabolism, and clinical response to ara-C-containing TST was evaluated by comparing AML marrow cell growth kinetic and biochemical pharmacologic determinants obtained before therapy (day 0) and at the predicted peak of in vivo postdrug residual tumor proliferation (day 8). Serial measurements of DNA synthesis and net intracellular ara-C metabolism demonstrated marked increases in both determinants in day 8 residual tumor when compared with the pretreatment cells for newly diagnosed adults achieving complete remission b ut not for TST-refractory patients. The interrelationship of AML cell proliferation and biochemical pharmacology together quantitate cytotoxicity measured by both achievement and duration of remission and serve to predict eventual clinical outcome in response to TST with ara-C where both growth and favorable pharamcokinetics are intrinsic to the success of the drug schedule.

Original languageEnglish (US)
Pages (from-to)24-30
Number of pages7
Issue number1
StatePublished - 1989

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia'. Together they form a unique fingerprint.

Cite this